OBJECTIVE: To evaluate the efficacy and safety of anti-interleukin-17 antibody in the treatment of plaque psoriasis. METHDOS: Randomized controlled trials (RCT) of anti-interleukin-17 antibody (Secukinumab, Brodalumab, and Ixekizumab) in the treatment of plaque psoriasis published between January, 2000 and March, 2017 were searched from PubMed, Cochrane Library, EBSCO, EMbase, CBM, CNKI, VIPdetabase, and Wangfang database. The quality of the retrieved trials was evaluated and the results of studies were analyzed using RevMan 5.0 software. RESULTS: Thirteen RCTs were included involving a total of 11 203 patients. Meta-analysis showed a significant differences between anti-interleukin-17 antibody and placebo (or positive drug) in terms of PASI75 and sPGA (P<0.05). The total incidence of adverse events differed significantly between anti- interleukin-17 antibody and placebo, but no significant differences were found between them in the incidence of serious adverse events and discontinuation rate due to adverse events (P>0.05). CONCLUSION: Anti-interleukin-17 antibody is safe and effective for treatment of plaque psoriasis.
OBJECTIVE: To evaluate the efficacy and safety of anti-interleukin-17 antibody in the treatment of plaque psoriasis. METHDOS: Randomized controlled trials (RCT) of anti-interleukin-17 antibody (Secukinumab, Brodalumab, and Ixekizumab) in the treatment of plaque psoriasis published between January, 2000 and March, 2017 were searched from PubMed, Cochrane Library, EBSCO, EMbase, CBM, CNKI, VIPdetabase, and Wangfang database. The quality of the retrieved trials was evaluated and the results of studies were analyzed using RevMan 5.0 software. RESULTS: Thirteen RCTs were included involving a total of 11 203 patients. Meta-analysis showed a significant differences between anti-interleukin-17 antibody and placebo (or positive drug) in terms of PASI75 and sPGA (P<0.05). The total incidence of adverse events differed significantly between anti- interleukin-17 antibody and placebo, but no significant differences were found between them in the incidence of serious adverse events and discontinuation rate due to adverse events (P>0.05). CONCLUSION: Anti-interleukin-17 antibody is safe and effective for treatment of plaque psoriasis.
Authors: Mark Lebwohl; Bruce Strober; Alan Menter; Kenneth Gordon; Jolanta Weglowska; Lluis Puig; Kim Papp; Lynda Spelman; Darryl Toth; Francisco Kerdel; April W Armstrong; Georg Stingl; Alexa B Kimball; Herve Bachelez; Jashin J Wu; Jeffrey Crowley; Richard G Langley; Tomasz Blicharski; Carle Paul; Jean-Philippe Lacour; Stephen Tyring; Leon Kircik; Sergio Chimenti; Kristina Callis Duffin; Jerry Bagel; John Koo; Gary Aras; Joanne Li; Wenjie Song; Cassandra E Milmont; Yifei Shi; Ngozi Erondu; Paul Klekotka; Brian Kotzin; Ajay Nirula Journal: N Engl J Med Date: 2015-10 Impact factor: 91.245
Authors: Christopher E M Griffiths; Kristian Reich; Mark Lebwohl; Peter van de Kerkhof; Carle Paul; Alan Menter; Gregory S Cameron; Janelle Erickson; Lu Zhang; Roberta J Secrest; Susan Ball; Daniel K Braun; Olawale O Osuntokun; Michael P Heffernan; Brian J Nickoloff; Kim Papp Journal: Lancet Date: 2015-06-10 Impact factor: 79.321
Authors: Kim A Papp; Craig Leonardi; Alan Menter; Jean-Paul Ortonne; James G Krueger; Gregory Kricorian; Girish Aras; Juan Li; Chris B Russell; Elizabeth H Z Thompson; Scott Baumgartner Journal: N Engl J Med Date: 2012-03-29 Impact factor: 91.245
Authors: Kenneth B Gordon; Andrew Blauvelt; Kim A Papp; Richard G Langley; Thomas Luger; Mamitaro Ohtsuki; Kristian Reich; David Amato; Susan G Ball; Daniel K Braun; Gregory S Cameron; Janelle Erickson; Robert J Konrad; Talia M Muram; Brian J Nickoloff; Olawale O Osuntokun; Roberta J Secrest; Fangyi Zhao; Lotus Mallbris; Craig L Leonardi Journal: N Engl J Med Date: 2016-06-08 Impact factor: 91.245